Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
The prevalence of atopic dermatitis (AD) in industrialized countries has increased exponentially over the past three decades, currently affecting 15 to 30% of children and up to 10% of adults.1 At the recent official launch event of pimecrolimus (Elidel®, Meda Healthcare Sdn. Bhd.) held at Le Méridien Kuala Lumpur, Professor Thomas Luger provided insights on the pathophysiology of AD and the role of topical calcineurin inhibitors (TCIs) in the management of AD.
Allergic rhinitis (AR) is a common global health problem that poses a significant impact on the quality of life and productivity of affected patients. At the Ear, Nose and Throat (ENT) Summit 2017 held recently at Hilton Sentral, Kuala Lumpur, Malaysia, Associate Professor Marysia P Tiongco-Recto was invited by A. Menarini to deliver a lecture on the potential of modern second-generation antihistamines, particularly bilastine (Bilaxten®) in the management of AR.
Nutrition and Behaviour Modification for Picky Eaters (NBMPE) is a management plan for children with mild picky eating habits. An NBMPE Expert Programme was recently conducted by three of the expert panelists in Kuala Lumpur, which saw the participation of more than 30 paediatricians from across the country. The highlights from the event are summarized here.
At the 57th Annual Scientific Congress of the Private Medical Practitioners Association of Selangor and Kuala Lumpur (PMPASKL), Professor Dr Jamal I-Ching Sam spoke on the impact of influenza in Malaysia and preventive strategies against it. Highlights from his presentation are summarized below.
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
A recent study has found that food bolus impaction or strictures predict most episodes of oesophageal perforation, a rare but serious complication of eosinophilic esophagitis (EoE) that occurs in about 2 percent of cases. This suggests that patients with fibrostenotic disease due to longer duration of symptoms are at increased risk.